FDA greenlights Nerivio for prevention
The FDA approved Theranica’s wearable Nerivio for preventive treatment of migraine, expanding the device’s cleared uses beyond acute relief. The regulatory decision was reported April 13, 2026 and is part of a trend of wearables moving into therapeutic roles. (neurologylive.com)
Migraine treatment is splitting into two jobs: stopping an attack once it starts and cutting down how often attacks happen. The Food and Drug Administration has cleared Theranica’s Nerivio wearable to do both, adding prevention to its earlier acute-use clearance. (neurologylive.com, fda.gov) Nerivio is a prescription device worn on the upper arm, not the head. It delivers remote electrical neuromodulation, meaning mild electrical pulses meant to trigger the body’s own pain-control pathways, and it is controlled through a smartphone app. (accessgudid.nlm.nih.gov, nerivio.com) For prevention, the labeled schedule is every other day at home. For acute treatment, patients use it at the onset of migraine headache or aura, and the same device now carries both uses on its indication. (nerivio.com, accessgudid.nlm.nih.gov) The preventive clearance was backed by a randomized, double-blind, placebo-controlled trial in 248 patients with episodic and chronic migraine. In that study, Nerivio users had a mean reduction of 4.0 migraine days per month from baseline, versus 1.3 days in the placebo group. (neurologylive.com, clinicalpainadvisor.com, prnewswire.com) A later analysis of the same study found separation from placebo within weeks, not months. Theranica said monthly migraine days were down by 1.7 after two weeks with Nerivio, compared with 0.8 in the placebo group, and by 3.1 after four weeks, compared with 1.5 in placebo. (nerivio.com, prnewswire.com) The regulatory timeline is older than the April 13, 2026 write-up that resurfaced the story. The Food and Drug Administration clearance letter is dated February 6, 2023, and NeurologyLive published its report on February 28, 2023. (fda.gov, neurologylive.com) What has changed since then is the label around who can use it. Current Nerivio safety and indication pages say the device is indicated for patients 8 years and older, while the 2023 clearance and coverage reports described the preventive use in patients 12 and older. (nerivio.com, fda.gov, empr.com) The device is not for everyone. Nerivio says people with uncontrolled epilepsy or an active implanted electronic device such as a pacemaker should not use it, and it says the device has not been evaluated in people with congestive heart failure, severe cardiac disease, severe cerebrovascular disease, or children younger than 8. (nerivio.com) The business case has also widened as the clinical one did. Theranica said in February 2026 that coverage for Nerivio had reached about 130 million lives, after policy expansions that recognized the wearable for both acute and preventive migraine treatment. (prnewswire.com, theranica.com) Nerivio now sits in a small but growing class of wearables that are sold as therapy, not just tracking hardware. In migraine care, that means one arm-worn prescription device is being positioned as both the thing patients reach for during an attack and the thing they use every other day to try to have fewer of them. (accessgudid.nlm.nih.gov, nerivio.com)
